Adverse drug events : interconsultations in hospitalized patients in the HUMV

Adverse drug reactions (ADRs) are a health problem on the rise, and therefore it requires a detailed study. For this reason, a retrospective study of the consultants is performed by the Allergology service of the University Hospital Marqués de Valdecilla (HUMV). Objectives: establish the prevalence of ADRs in our hospital, as well as know the risk factors for them and its main characteristics, determine the drugs involved and establish comparisons with known epidemiological data. Results: the prevalence of ADRs reported in the HUMV is really low (0,53 %). The services of medical nature made more notifications than the surgical. The advance age and polypharmacy are risk factors for a ADR. The drugs involved in a greater number of cases are antibiotic, iodinated contrast and NSAIDs. Conclusions: we think that ADRs are underreported, so that professionals should become aware about the importance of the RAM’s notification, which also in many cases are avoidable. We should try to avoid polypharmacy whenever possible, because it may be producing less adverse reactions.ABSTRACT: Las reacciones adversas medicamentosas (RAM) son un problema sanitario en auge, por lo que requiere un estudio minucioso del mismo. Por este motivo se realiza un estudio retrospectivo sobre las interconsultas realizadas el servicio de Alergología del Hospital Universitario Marqués de Valdecilla (HUMV). Objetivos: establecer la prevalencia de las RAM en nuestro hospital, así como conocer los factores de riesgo de las mismas y sus características principales, determinar los fármacos implicados y establecer comparaciones con los datos epidemiológicos conocidos. Resultados: la prevalencia de RAM notificadas en el HUMV es extremadamente baja (0,53%). Los servicios de carácter médico realizan más notificaciones que los quirúrgicos. La edad avanzada y la polimedicación son factores de riesgo que predisponen a RAM. Los fármacos implicados en un mayor número de casos son los antibióticos, el contraste yodado y los AINEs. Conclusiones: creemos que las RAM están infranotificadas, por lo que los profesionales debemos concienciarnos sobre la importancia de la comunicación de las mismas, que además en muchos casos son evitables. Especialmente importante es intentar evitar la polimedicación siempre que sea posible.Grado en Medicin

Adjusted global antiphospholipid syndrome score (aGAPSS) is useful to predict relapses in patients with retinal vein occlusion

Background A significant proportion of patients with retinal vein occlusion (RVO) are antiphospholipid antibodies (aPL) carriers. Relapsing disease occurs in nearly 10 % of cases and the role of aPL has not been established. The adjusted global antiphospholipid syndrome score (aGAPSS) was developed to assess the risk of clinical events in aPL carriers and its role in the management of RVO patients is unknown. Objective To analyze the values of aGAPSS in a large cohort of patients with RVO and population-based controls, and to assess its usefulness to predict RVO relapses. Methods Case-control study of RVO patients and population-based controls of similar age and sex. We have assessed and compared the aPL profile and the aGAPSS score in patients with and without relapsing disease and controls. Results Four-hundred and seventy-two RVO patients and 346 controls were included. Fifty-seven RVO patients had antiphospholipid syndrome (RVO-APS). Of them, 75.4 % had a high-risk profile compared to 3 % in controls (p = 0.0001). The median aGAPSS values were 8 [7?13], 3 [1?4], and 3 [0?4], in RVO-APS, RVO no-APS, and controls. Nineteen patients had had a recurrence of RVO before inclusion and 8 during the follow-up. APS was more prevalent in relapsing patients. In the adjusted multivariable regression model, the best predictor for RVO recurrence during the follow-up was an aGAPSS score ?6 (OR 5.5, CI95% 1.3?23.7; p = 0.023). Conclusions In patients with RVO, once the control of vascular risk factors has been optimized, the aGAPSS might help to identify those at risk of relapsing disease.Sources of funding: The Camargo Cohort Study was supported by a grant from Instituto de Salud Carlos III (PI21/00532) that could be co-funded by European Union FEDER funds